Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers

NCT03184168 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03184168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 5, 2017
Completion date
August 25, 2017
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers